-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SR-1375 in Community Acquired Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SR-1375 in Community Acquired Pneumonia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SR-1375 in Community Acquired Pneumonia Drug Details: SR-1375 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SR-1375 in Hospital Acquired Pneumonia (HAP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SR-1375 in Hospital Acquired Pneumonia (HAP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SR-1375 in Hospital Acquired Pneumonia (HAP) Drug Details: SR-1375 is...
-
Thematic Analysis
NewRetail M&A Deals Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Retail Sector
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Axitinib SR in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Axitinib SR in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Axitinib SR in Wet (Neovascular / Exudative)...
-
Product Insights
SRS – Helianto Photovoltaic Park 80 MW – Sardinia
The SRS – Helianto Photovoltaic Park 80 MW – Sardinia project involves the construction of a 80MW solar power plant in Cagliari, Sardinia, Italy. Equip yourself with the essential tools needed to make informed and profitable decisions with our SRS – Helianto Photovoltaic Park 80 MW – Sardinia report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mibavademab in Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mibavademab in Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mibavademab in Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FOG-001 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FOG-001 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FOG-001 in Solid Tumor Drug Details: FOG-001 is under development of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-1908 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-1908 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-1908 in Gastric Cancer Drug Details: LB-1908 (LCAR-C18S) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMG-305 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMG-305 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMG-305 in Colorectal Cancer Drug Details: Monoclonal antibody is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tobemstomig in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tobemstomig in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tobemstomig in Triple-Negative Breast Cancer (TNBC) Drug Details: RG-6139...